Psoriasis and non-alcoholic fatty liver disease

Journal of the European Academy of Dermatology and Venereology

Volumn 25, Issue 4, 2011, Pages 383-391

  Wenk, K S ^a   Arrington, K C ^b   Ehrlich, A ^a  

^a GEORGE WASHINGTON UNIVERSITY   (United States)

^b GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

adipokines; hepatic steatosis; metabolic syndrome; non alcoholic fatty liver disease; psoriasis; steatohepatitis

Indexed keywords

ADIPOCYTOKINE; CYTOKINE; LIPID;

CHRONIC INFLAMMATION; DISEASE ASSOCIATION; DISEASE SEVERITY; HUMAN; INSULIN RESISTANCE; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; OBESITY; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; PSORIASIS; REVIEW;

ADIPOKINES; ADULT; FATTY LIVER; FEMALE; HUMANS; INSULIN RESISTANCE; LIPID METABOLISM; LIVER; MALE; MIDDLE AGED; PSORIASIS;

EID: 79952372812     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2010.03841.x     Document Type: Review

References (86)

1. Gottlieb AB, Chao C, Dann F,. Psoriasis comorbidities. J Dermatol Treat 2008; 19: 5-21. (Pubitemid 351252710)
2. Third Report of the National Cholesterol Eduction Program (NCEP). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-3421.
3. Hamaguchi M, Kojima T, Takeda N, et al. The Metabolic Syndrome as a Predictor of Nonalcoholic Fatty Liver Disease. Ann Intern Med 2005; 143: 722-728.
4. Preiss D, Sattar N,. Non-alcoholic fatty liver disease: an overview of prevalence, diagnosis, pathogenesis, and treatment considerations. Clin Sci 2008; 115: 141-150.
5. Lazo M, Clark JM,. The epidemiology of nonalcoholic fatty liver disease: a global perspective. Semin Liver Dis 2008; 28: 339-350.
6. Adams LA, Talwalkar JA,. Diagnostic evaluation of nonalcoholic fatty liver disease. J Clin Gastroenterol 2006; 40: S34-S38. (Pubitemid 44309541)
7. Szczepaniak LS, Nurenberg P, Leonard D, et al. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab 2005; 288: E462-E468. (Pubitemid 40110657)
8. Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004; 40: 1387-1395. (Pubitemid 39657013)
9. Wanless IR, Lentz JS,. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 1990; 12: 1106-1110.
10. Ong JP, Elariny H, Collantes R, et al. Predictors of nonalcoholic steatohepatitis and advanced fibrosis in morbidly obese patients. Obes Surg 2005; 15: 310-315. (Pubitemid 40463594)
11. Lonardo A, Loria P, Carulli N,. Concurrent non-alcoholic steatohepatitis and psoriasis. Report of three cases from the POLI.ST.E.N.A. study. Dig Liver Dis 2001; 33: 86-87. (Pubitemid 32186183)
12. Matsumoto T, Suziki N, Watanabe H, et al. Nonalcoholic steatohepatitis associated with psoriasis vulgaris. J Gastroenterol 2004; 39: 1102-1105. (Pubitemid 39618795)
13. Gisondi P, Targher G, Zoppini G, Girolomoni G,. Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol 2009; 51: 758-764.
14. Miele L, Vallone S, Cafalo C, et al. Prevalence, characteristics and severity of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J of Hepatol 2009; 51: 778-786.
15. Lee YH, Pratley RE,. The evolving role of inflammation in obesity and the metabolic syndrome. Curr Diab Rep 2005; 5: 70-75. (Pubitemid 40277804)
16. Setty AR, Curhan G, Choi HK,. Obesity, waist circumference, weight change, and the risk of psoriasis in women. Arch Intern Med 2007; 167: 1670-1675. (Pubitemid 47280349)
17. Edens MA, Kuipers F, Stolk RP,. Non-alcoholic fatty liver disease is associated with cardiovascular disease risk markers. Obes Rev 2009; 10: 412-419.
18. Parekh S, Anania FA,. Abnormal lipid and glucose metabolism in obesity: implications for nonalcoholic fatty liver disease. Gastroenterology 2007; 132: 2191-2207. (Pubitemid 46693752)
19. Saadeh S, Younossi ZM, Remer EM, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002; 123: 745-750. (Pubitemid 34977081)
20. Kang H, Greenson JK, Omo JT, et al. Metabolic syndrome is associated with greater histologic severity, higher carbohydrate, and lower fat diet in patients with NAFLD. Am J Gasteroenterol 2006; 101: 2247-2253. (Pubitemid 44477551)
21. Shimano H, Horton JD, Hammer RE, et al. Overexpression of cholesterol and fatty acids causes massive liver enlargement in transgenic mice expressing truncated SREBP-1a. J Clin Invest 1996; 98: 1575-1584. (Pubitemid 26327867)
22. Yahagi N, Shimano H, Hasty AH, et al. Absence of sterol regulatory element-binding protein-1 (SREBP-1) ameliorates fatty livers but not obesity or insulin resistance in Lep(ob)/Lep(ob) mice. J Biol Chem 2002; 277: 19353-19357. (Pubitemid 34967441)
23. Wolfrum C, Asilmaz E, Luca E, et al. Foxa2 regulates lipid metabolism and ketogenesis in the liver during fasting and in diabetes. Nature 2004; 432: 1027-1032. (Pubitemid 40052233)
24. Kim CH, Younossi ZM,. Nonalcoholic fatty liver disease: a manifestation of the metabolic syndrome. Cleve Clin J Med 2008; 5: 721-728.
25. Belfort R, Harrison SA, Brown K, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Eng J Med 2006; 355: 2297-2307. (Pubitemid 44837778)
26. Brenelli SL, Moraes AM, Monte-Allegre S, et al. Insulin resistance in psoriasis. Braz J Med Biol Res 1995; 28: 297-301.
27. Boehncke S, Thaci D, Beschmann H,. Psoriasis patients show signs of insulin resistance. Br J Dermatol 2007; 157: 1249-1251. (Pubitemid 350115673)
28. Ucak S, Ekmekci T, Basat O,. Comparison of various insulin sensitivity indices in psoriatic patients and their relationship with types of psoriasis. J Eur Acad Dermatol Venereol 2006; 20: 517-522.
29. Shafiq N, Malhotra S, Pandhi P, et al. Pilot trial: Pioglitazone verses placebo in patients with plaque psoriasis (the P6). Int J Dermatol 2005; 44: 328-333. (Pubitemid 40542153)
30. Martinez Abundis E, Reynoso-von DC, Hernandez-Salazar E, Gonzalez-Ortiz M,. Effect of etanercept on insulin secretion and insulin sensitivity in a randomized trial with psoriatic patients at risk for developing type 2 diabetes mellitus. Arch Dermatol Res 2007; 299: 461-465. (Pubitemid 47546924)
31. Marra M, Campanati A, Testa R, et al. Effect of etanercept on insulin sensitivity in nine patients with psoriasis. Int J Immunopathol Pharmacol 2007; 20: 731-736.
32. Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS,. Protection from obesity-induced insulin resistance in mice lacking TNF-α function. Nature 1997; 389: 610-614. (Pubitemid 27446179)
33. Veroux M, Corona D, Giuffrida G, et al. New-onset diabetes mellitus after kidney transplantation: the role of immunosuppression. Transplant Proc 2008; 40: 1885-1887.
34. Vozarova B, Weyer C, Hanson K, et al. Circulating interleukin-6 in relation to adiposity, insulin action, and insulin secretion. Obes Res 2001; 9: 414-417. (Pubitemid 33603868)
35. Hotamisligil G, Spiegelman BM,. Tumor necrosis factor alpha: a key component of the obesity-diabetes link. Diabetes 1994; 43: 1271-1278.
36. Weyer C, Yudkin JS, Stehouwer CD, et al. Humoral markers of inflammation and endothelial dysfunction in relation to adiposity and in vivo insulin action in Pima Indians. Atherosclerosis 2002; 161: 233-242. (Pubitemid 34214841)
37. Kern PA, Saghizadeh M, Ong JM, et al. The expression of tumor necrosis factor in human adipose tissue. J Clin Invest 1995; 95: 2111-2119.
38. Jarrar MH, Baranova A, Collantes R,. Adipokines and cytokines in non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2008; 27: 412-421.
39. Wajchenberg BL, Giannella-Neto D, da Silva ME, Santos RF,. Depot-specific hormonal characteristics of subcutaneous and visceral adipose tissue and their relation to metabolic syndrome. Horm Metabol Res 2002; 34: 616-621. (Pubitemid 36398695)
40. Depres JP, Lemieux I, Bergeron J, et al. Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk. Arterioscler Thromb Vasc Biol 2008; 28: 1039-1049.
41. Diehl AM,. Tumor necrosis factor and its potential role in insulin resistance and nonalcoholic fatty liver disease. Clin Liver Dis 2004; 8: 619-638. (Pubitemid 39141146)
42. Hui JM, Hodge A, Farrell GC, et al. Beyond Insulin Resistance in NASH: TNF-α or Adiponectin? Hepatology 2004; 40: 46-54. (Pubitemid 38868922)
43. Xu A, Wang Y, Keshaw H, et al. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest 2003; 112: 91-100. (Pubitemid 38056380)
44. Wolf AM, Wolf D, Rumpold H, et al. Adiponectin induces the anti-inflammatory cytokines IL-10 and IL-1RA in human leukocytes. Biochem Biophys Res Commun 2004; 323: 630-635. (Pubitemid 39221142)
45. Wulster-Radcliffe MC, Ajuwon KM, Wang J, et al. Adiponectin differentially regulates cytokines in porcine macrophages. Biochem Biophys Res Commun 2004; 316: 924-929. (Pubitemid 38368041)
46. Takahashi H, Tsuji H, Takahashi I, et al. Plasma adiponectin and leptin levels in Japanese patients with psoriasis. Br J Dermatol 2008; 159: 1207-1214.
47. Krueger G, Ellis CN,. Psoriasis-recent advances in understanding its pathogenesis and treatment. J Am Acad Dermatol 2005; 53: 294-100.
48. Racz E, Prens EP,. Molecular pathophysiology of psoriasis and molecular targets of antipsoriatic therapy. Expert Rev Mol Med 2009; 11: e38.
49. Cerman AA, Bozkurt S, Sav A, et al. Serum leptin levels, skin leptin and leptin receptor expression in psoriasis. Br J Dermatol 2008; 159: 820-826.
50. Chitturi S, Farrell G, Frost L, et al. Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: a manifestation of lipotoxicity? Hepatology 2002; 36: 403-409. (Pubitemid 34810360)
51. Uygun A, Kadayifci A, Yesilova Z, et al. Serum leptin levels in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2000; 95: 3584-3589.
52. Chalasani N, Crabb DW, Cummings OW, et al. Does leptin play a role in the pathogenesis of human nonalcoholic steatohepatitis? Am J Gastroenterol 2003; 98: 2771-2776. (Pubitemid 38020122)
53. Wang Y, Chen J, Zhao Y, et al. Psoriasis is associated with increased levels of serum leptin. Br J Dermatol 2008; 158: 1134-1135. (Pubitemid 351521426)
54. Chen Y, Wu C, Shen J, et al. Psoriasis independently associated with hyperleptinemia contributing to metabolic syndrome. Arch Dermatol 2008; 144: 1571-1575.
55. Johnston A, Arnadottir S, Gudjonsson JE, et al. Obesity in psoriasis: leptin and resistin as mediators of cutaneous inflammation. Br J Dermatol 2008; 159: 342-350. (Pubitemid 352009847)
56. Gudjonsson JE, Johnston A, Sigmundsdottir H, Valdimarsson H,. Immunopathogenic mechanisms in psoriasis. Clin Exp Immunol 2004; 135: 1-8. (Pubitemid 38067920)
57. Wieckowska A, Papouchado BG, Li Z, et al. Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis. Am J Gastroenterol 2008; 103: 1372-1379. (Pubitemid 351813900)
58. Tilg H, Hotamisligil GS,. Nonalcoholic fatty liver disease: Cytokine-adipokine interplay and regulation of insulin resistance. Gastroenterology 2006; 131: 934-945. (Pubitemid 44307061)
59. Itoh S, Kanazuka A, Akimoto T,. Combined treatment with ursodeoxycholic acid and pioglitazone in a patient with nash associated with type 2 diabetes and psoriasis. Dig Dis Sci 2003; 48: 2182-2186. (Pubitemid 38037306)
60. Itoh S, Kono M, Akimoto T,. Psoriasis treated with ursodeoxycholic acid: three case reports. Clin Exp Dermatol 2007; 32: 398-400. (Pubitemid 46828315)
61. Feldstein AE, Werneburg NW, Canbay A, et al. Free fatty acids promote hepatic lipotoxicity by stimulating TNF-α expression via a lysosomal pathway. Hepatology 2004; 40: 185-194. (Pubitemid 38868937)
62. Kalb RE, Strober B, Weinstein G, Lebwohl M,. Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference. J Am Acad Dermatol 2009; 60: 824-837.
63. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol 2009; 61: 451-485.
64. Berends MAM, van Oijen MGH, Snoek J, et al. Reliability of the Roenigk classification of liver damage after methotrexate treatment for psoriasis: a clinicopathologic study of 160 liver biopsy specimens. Arch Dermatol 2007; 143: 1515.
65. Langman G, De la M Hall P, Todd G,. Role of non-alcoholic steatohepatitis in methotrexate-induced liver injury. J Gastroenterol Hepatol 2001; 16: 1395-1401. (Pubitemid 34107409)
66. Roenigk HH, Callen JP, Guzzo CA, et al. Effects of acitretin on the liver. J Am Acad Dermatol 1999; 41: 584-588. (Pubitemid 29480409)
67. Hagar HH,. The protective effect of taurine against cyclosporine A-induced oxidative stress and hepatotoxicity in rats. Toxicol Lett 2004; 151: 335-343. (Pubitemid 38759297)
68. Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005; 366: 1367-1374. (Pubitemid 41443403)
69. Fairhurst DA, Sheehan-Dare R,. Autoimmune hepatitis associated with infliximab in a patient with palmoplantar pustular psoriasis. Clin Exp Dermatol 2009; 34: 421-422.
70. Tobon GJ, Canas C, Jaller JJ, et al. Serious liver disease induced by infliximab. Clin Rheum 2007; 26: 578-581. (Pubitemid 46359303)
71. Ostuni P, Botsios C, Punzi L, et al. Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate. Ann Rheum Dis 2003; 62: 686-687. (Pubitemid 36760576)
72. Montiel PM, Solis JA, Chirinos JA, et al. Hepatitis B reactivation during therapy with etanercept in an HBsAg-negative and anti-HBs-positive patient. Liver Int 2008; 28: 718-720.
73. Farah M, Rashidi AA, Owen DA, et al. Granulomatous hepatitis associated with etanercept therapy. J Rheum 2008; 35: 349-351. (Pubitemid 351281159)
74. Adar T, Mizrahi M, Pappo O, et al. Adalimumab-induced Autoimmune Hepatitis. J Clin Gastroenterol 2010; 44: e20-e22.
75. Hartmann U, Schmitt S, Reuss-Borst M,. Elevated liver enzymes in rheumatoid arthritis: differential diagnostic considerations based on a case report. Z Rheumatol 2008; 67: 440-444.
76. Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008; 371: 1665-1674. (Pubitemid 351671883)
77. Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008; 371: 1675-1684. (Pubitemid 351671884)
78. Schramm C, Schneider A, Marx A, et al. Adalimumab could suppress the activity of non-alcoholic steatohepatitis (NASH). Z Gastroenterol 2008; 46: 1369-1371.
79. Li Z, Yang S, Lin H, et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology 2003; 37: 343-350. (Pubitemid 36152533)
80. Barbuio R, Milanski M, Bertolo MB, et al. Infliximab reverses steatosis and improves insulin signal transduction in liver of rats fed a high-fat diet. J Endocrinol 2007; 194: 539-550. (Pubitemid 47471222)
81. Tilg H, Day CP,. Management strategies in alcoholic liver disease. Gastroenterol Hepatol 2007; 4: 24-34. (Pubitemid 46055957)
82. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-1321. (Pubitemid 40770284)
83. Cohen AD, Sherf M, Vidavsky L, et al. Association between psoriasis and the metabolic syndrome. A cross-sectional study. Dermatology 2008; 216: 152-155. (Pubitemid 351158580)
84. Gisondi P, Tessari G, Conti A, et al. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br J Dermatol 2007; 157: 68-73. (Pubitemid 46934281)
85. Sommer DM, Jenisch S, Suchan M, et al. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res 2006; 298: 321-328.
86. Prey S, Paul C, Bronsard V, et al. Cardiovascular risk factors in patients with plaque psoriasis: a systematic review of epidemiological studies. J Eur Acad Dermatol Venereol 2010; 24: 23-30.